tirzepatide blood test has unique activity to stimulate insulin secretion, suggests study Tirzepatide 10mg — GLP-1/GIP Dual-Agonist

This transparent, non-tiered approach removes cost barriers as your treatment progresses and your dose is adjusted for optimal results

PACKAGE LABEL MOUNJARO KwikPen 12.5 mg per dose (50 mg/2.4 mL [20.8 mg/mL]) NDC 0002-3422-11 Rx Only Mounjaro KwikPen (tirzepatide) injection 12.5 mg per dose 50 mg/2.4 mL (20.8 mg/mL) 1 Pen with 4 doses of 12.5 mg TURN THE DOSE KNOB ALL THE WAY UNTIL YOU SEE A

Currently marketed GLP-1 patches contain herbal ingredients that have shown improvements in metabolism and appetite suppression in individual studies, yet no clinical trials or research show their significant combined effect in weight loss

Further implicating GLP-1 in the increased insulin response, administration of the GLP-1 receptor antagonist exendin(9-39) has been found to impair insulin response to an oral glucose load in both humans and rodents (39, 7173)

and lying down for 15 minutes after eating

Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby